The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://jasonaqob968580.blogunteer.com/37589430/retatrutide-vs-tirzepatide-a-comparative-analysis